Literature DB >> 10444516

Expression and activation of protein kinase C-zeta in eosinophils after allergen challenge.

D J Evans1, M A Lindsay, B L Webb, H Kankaanranta, M A Giembycz, B J O'Connor, P J Barnes.   

Abstract

Protein kinase (PK) C is an increasingly diverse family of enzymes that has been implicated in a range of cellular functions within the eosinophil. Using isoform-specific polyclonal antibodies, we have explored the expression of PKC isoforms in circulating eosinophils. Initial studies demonstrated the presence of the alpha, betaI, betaII, and zeta and the low-level expression of the delta, epsilon, iota, and micro isoforms but no detectable expression of the gamma, eta, and theta isoforms in both normal and asthmatic subjects. There was no difference in the total protein expression between these two groups. Subsequent studies examined the expression and activation of PKC isoforms in circulating eosinophils from asthmatic patients before and 24 h after a late asthmatic response to an inhaled allergen. Cellular fractionation showed PKC-alpha and PKC-betaII to be mainly located in the cytosol, whereas PKC-betaI was constitutively more expressed in the membrane. No changes in expression or subcellular localization of these isoforms were seen after allergen challenge. In contrast, PKC-zeta expression was increased after allergen challenge, and we demonstrated a significant PKC-zeta translocation to the membrane, in keeping with activation of the enzyme. Our results suggest that 24 h after allergen exposure of asthmatic patients, there is increased expression and activation of eosinophil PKC-zeta that correlates with late asthmatic responses recorded between 4 and 10 h postallergen challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444516     DOI: 10.1152/ajplung.1999.277.2.L233

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; P G Hellewell; M A Lindsay
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Regulation of interleukin-5-induced beta2-integrin adhesion of human eosinophils by phosphoinositide 3-kinase.

Authors:  Masaaki Sano; Alan R Leff; Shigeharu Myou; Evan Boetticher; Angelo Y Meliton; Jonathan Learoyd; Anissa T Lambertino; Nilda M Munoz; Xiangdong Zhu
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03-31       Impact factor: 6.914

3.  An atypical protein kinase C, PKC zeta, regulates human eosinophil effector functions.

Authors:  Masahiko Kato; Takafumi Yamaguchi; Atsushi Tachibana; Masato Suzuki; Takashi Izumi; Kenichi Maruyama; Yasuhide Hayashi; Hirokazu Kimura
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

4.  Protein kinase C activation inhibits eosinophil degranulation through stimulation of intracellular cAMP production.

Authors:  Charles I Ezeamuzie; Najla Taslim
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  Pharmacological comparison of LTB(4)-induced NADPH oxidase activation in adherent and non-adherent guinea-pig eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; M A Lindsay
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Pin1 regulates TGF-beta1 production by activated human and murine eosinophils and contributes to allergic lung fibrosis.

Authors:  Zhong-Jian Shen; Stephane Esnault; Louis A Rosenthal; Renee J Szakaly; Ronald L Sorkness; Pamela R Westmark; Matyas Sandor; James S Malter
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

7.  Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT.

Authors:  Shigeharu Myou; Alan R Leff; Saori Myo; Evan Boetticher; Jiankun Tong; Angelo Y Meliton; Jie Liu; Nilda M Munoz; Xiangdong Zhu
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.